엑셀세라퓨틱스

373110KOSDAQ기초 의약물질 제조업

47.4 / 100

Reference Date: 2026-07-24

Financial Score10.5 / 40

News Sentiment20.9 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 1.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Excel Therapeutics focuses on the cell culture media market essential for cell and gene therapy (CGT) development, targeting the rapidly growing cell therapy segment, which is projected to expand from $64 billion in 2024 to $306 billion by 2034. The company is diversifying its business into cultivated meat, cosmetics, artificial blood, and other fields, while advancing domestic media production through continuous R&D.

Number of Employees

65people

Average Salary

66.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

2.90Industry Average 1.260.0Point

2.3x industry avg (risky)

ROE

-134.41Industry Average -6.033.5Point

22.3x industry avg (excellent)

Debt Ratio

45.55Industry Average 6.620.0Point

6.9x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -157.0% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 7Neutral 0Negative 0Average Sentiment Score 83.6

Positive
엑셀세라퓨틱스, 獨 PL 바이오와 공급계약…유럽 시장 공략
엑셀세라퓨틱스는 독일 PL 바이오사이언스와의 공급계약을 통해 유럽 시장 진출을 확대하며 긍정적인 성장 전망을 보임.
Positive
엑셀, 유럽 첫 진출…"독일 PL바이오와 공급계약"
엑셀세라퓨틱스의 유럽 시장 진출로 인해 글로벌 판매 네트워크 확장 기대.
Positive
엑셀, "메디포스트 '카티스템' 생산 인프라 고도화"
엑셀세라퓨틱스의 용인GMP 배지생산시설 고도화로 카티스템 생산 인프라 구축이 본격화되어 미래 성장 가능성이 높아졌다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 1,199Won52-week high 3,34052-week low 1,121

1-month return3.0Point

1m -1.56% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0